Abstract: Pyridazine compounds for inhibiting NaV1.8 and methods for treating a condition, disease, or disorder associated with an increased NaV1.8 activity or expression are disclosed.

Abstract: A fixing mechanism for fixing a first panel to a second panel, having a first plate with a first longitudinal guide, the first guide comprising a first aperture at a first end of the first guide connected to a second aperture at a second end of the first guide via a longitudinal slot, the first aperture is greater than the second aperture; a second plate having a second guide complementary to the first guide, a retaining portion, an interlocking member configured to fasten the second plate to the first plate via the first and second guides and also to fasten the first and second plates to the first panel. The first plate and the second plate are fastened to the second panel via a second fastening means. The fixing mechanism advantageously provides a means for securely fixing two panels together, such as furniture panels, using minimal components.

Abstract: Compounds of formula (I), formula (II), or formula (III) and their use with a neurological or psychiatric disorder, mediated by Kv11.1-3.1 containing potassium channels, including schizophrenia, are disclosed.

Abstract: Pyridine carboxamide compounds for inhibiting NaV1.8 and methods for treating a condition, disease, or disorder associated with an increased NaV1.8 activity or expression are disclosed.

Abstract: The present invention provides compounds and compositions which are positive allosteric modulators of GABA-A receptors that selectively target the peripheral nervous system and organs of the body, and which do not pass through the blood-brain barrier. The compounds and compositions of the present invention are useful for treatment of diseases or disorders which are mediated by GABA-A neuronal activity, such as, for example, visceral pain, gut motility, irritable bowel syndrome, functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance.

Abstract: Pyridazine compounds for inhibiting NaV1.8 and methods for treating a condition, disease, or disorder associated with an increased NaV1.8 activity or expression are disclosed.

Abstract: This invention relates to compounds, pharmaceutical compositions and their use for treating neuropsychiatric and neurodegenerative disorders. In particular, the invention relates to inhibitors of catechol-O-methyltransferase and their use as therapeutics for central nervous system disease.

Abstract: Compounds that inhibit COMT enzyme and pharmaceutical compositions comprising the same are provided herein. Methods of treating various psychiatric and neurological disorders with the compounds and pharmaceutical compositions described herein are also provided.

Abstract: The present invention provides compounds and compositions which are positive allosteric modulators of GABA-A receptors that selectively target the peripheral nervous system and organs of the body, and which do not pass through the blood-brain barrier. The compounds and compositions of the present invention are useful for treatment of diseases or disorders which are mediated by GABA-A neuronal activity, such as, for example, visceral pain, gut motility, irritable bowel syndrome, functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance.

Abstract: Embodiments of the present disclosure present a calculated value within a card view presentation in order to overcome technical problems in presenting useful card view presentations on mobile computing devices. In some embodiments, the calculated value is a summary, analysis, or other type of information generated based on data associated with cards that are in a given lane. In some embodiments, further technical problems relating to the limitations of the interface of the mobile computing device in adjusting calculated view settings are addressed by presenting a simplified configuration interface. The simplified configuration interface presents a mobile-friendly view of limited configuration settings to allow the user to easily change settings relevant to the calculated value and/or the card view, and thereby adjust the card view despite the limitations of the interface of the mobile computing device.

Abstract: In some embodiments, a card view interface of tabular data is provided that is suitable for presentation on small displays such as those found on mobile computing devices. Cards from a single lane are displayed, along with a set of lane indicators. In some embodiments, when a drag operation is detected on a card, a size of the set of lane indicators is increased in order to facilitate dropping of the card on an intended lane indicator, thus helping to overcome the technical limitations of small mobile computing device displays.

Abstract: The present invention provides compounds and compositions which are positive allosteric modulators of GABA-A receptors that selectively target the peripheral nervous system and organs of the body, and which do not pass through the blood-brain barrier. The compounds and compositions of the present invention are useful for treatment of diseases or disorders which are mediated by GABA-A neuronal activity, such as, for example, visceral pain, gut motility, irritable bowel syndrome, functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance.

Abstract: Embodiments of the present disclosure present a calculated value within a card view presentation in order to overcome technical problems in presenting useful card view presentations on mobile computing devices. In some embodiments, the calculated value is a summary, analysis, or other type of information generated based on data associated with cards that are in a given lane. In some embodiments, further technical problems relating to the limitations of the interface of the mobile computing device in adjusting calculated view settings are addressed by presenting a simplified configuration interface. The simplified configuration interface presents a mobile-friendly view of limited configuration settings to allow the user to easily change settings relevant to the calculated value and/or the card view, and thereby adjust the card view despite the limitations of the interface of the mobile computing device.

Abstract: In some embodiments, a card view interface of tabular data is provided that is suitable for presentation on small displays such as those found on mobile computing devices. Cards from a single lane are displayed, along with a set of lane indicators. In some embodiments, when a drag operation is detected on a card, a size of the set of lane indicators is increased in order to facilitate dropping of the card on an intended lane indicator, thus helping to overcome the technical limitations of small mobile computing device displays.

Abstract: The present invention provides compounds and compositions which are positive allosteric modulators of GABA-A receptors that selectively target the peripheral nervous system and organs of the body, and which do not pass through the blood-brain barrier. The compounds and compositions of the present invention are useful for treatment of diseases or disorders which are mediated by GABA-A neuronal activity, such as, for example, visceral pain, gut motility, irritable bowel syndrome, functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance.

Abstract: The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.

Abstract: Disclosed are compositions and methods related to eukaryotic microorganisms that can produce unsaturated fatty acids which can be purified and used.

Abstract: Disclosed are compositions and methods related to eukaryotic microorganisms that can produce unsaturated fatty acids which can be purified and used.

Abstract: The present invention provides compounds and compositions which are positive allosteric modulators of GABA-A receptors that selectively target the peripheral nervous system and organs of the body, and which do not pass through the blood-brain barrier. The compounds and compositions of the present invention are useful for treatment of diseases or disorders which are mediated by GABA-A neuronal activity, such as, for example, visceral pain, gut motility, irritable bowel syndrome, functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance.

Abstract: Disclosed are microcapsules with shells that are not animal by-products and methods for preparing and using such microcapsules.